Review Article Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/pathology.2.020

Faecal Microbiota Transplantation as Primary Treatment for Clostridioidoes difficile Infection-evidence for Change

  • 1The Centre for Digestive Diseases, 229 Great North Road, Five Dock, Sydney, Australia
  • 2Axent Medical Pty Ltd, CSIRO Building 53, 11 Julius Avenue, North Ryde, Sydney, Australia
  • 3Progenabiome, 1845 Knoll Dr, Ventura, CA 93003, USA
+ Affiliations - Affiliations

Corresponding Author

Sibasish Dolai, Siba.Dolai@cdd.com.au; Thomas J Borody, Thomas.Borody@cdd.com.au

Received Date: May 15, 2021

Accepted Date: May 27, 2021


In this mini-review, we summarise the significant body of evidence for the treatment of Clostridioides difficile infection (CDI) with Faecal Microbiota Transplantation (FMT) and propose the transition of FMT from ‘last resort’ treatment to the forefront of CDI management. To address the feasibility of this proposal, we examined the rates of efficacy in FMT treated patients with CDI and also reviewed the safety of FMT across available published studies. A considered view of safety, efficacy, product standardisation, quality control and Good Manufacturing Practices (GMP) allows for a prudent approach in positioning FMT as the primary or initial treatment for CDI.


Faecal microbiota transplantation, Clostridioides difficile infection, Recurrent, Treatment, Safety, Efficacy, Donor screening, Colonoscopy, Nasogastric, Review

Author Information X